CBIH Announces Women-First Fertility Innovation Built on Nanoemulsion Delivery

About this update from Cannabis Bioscience International Holdings, Inc.

[{"type":"text","content":"Houston, Texas--(Newsfile Corp. - October 13, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) today announced the addition of a patent-pending nanoemulsion formulation to its growing portfolio, developed to support female fertility and reproductive function in women of advanced maternal age (35+). CBIH believes this innovation should expand evidence-based options for patients and partners.","length":415,"tagName":"p"},{"type":"text","content":"As age is a key determinant of reproductive outcomes—and first births are occurring later—the need for effective, evidence-based solutions is increasingly clear. In the United States, since 1990, birth rates have climbed 71% for women 35–39 and 127% for women 40–44. These trends, we believe, underscore the importance of approaches that protect ovarian reserve, enhance oocyte maturation, and support implantation.","length":415,"tagName":"p"},{"type":"text","content":""Despite these numbers, women's conditions continue to receive too little attention—underfunded and understudied relative to their burden," said Rosangel Andrades, MD, R&D Director. "Recent NIH budgets dedicate only about 8–9% to women's health. At CBIH, we believe we should help change that. We are committed to placing women at the center of innovation—listening with empathy, investing with intention, and advancing solutions that we expect will meet real needs from reproductive health to healthy aging, including unresearched conditions such as endometriosis and fibromyalgia," she added.","length":626,"tagName":"p"},{"type":"text","content":"CBIH's invention centers cannabinoids as the primary therapeutic drivers, integrating them with select antioxidants, polyphenols, fatty acids, and complementary bioactives to target the key mechanisms of age-related reproductive decline. Cannabinoids are positioned to modulate mitochondrial function, redox balance, and cytokine signaling within ovarian and endometrial tissues, with the goal of improving oocyte competence and endometrial receptivity. The nanoemulsion delivery system is engineered to enhance the solubility, colloidal stability, and bioavailability of these lipophilic cannabinoids, thereby we expect to increase tissue exposure at reproductive targets. By coupling cannabinoid-focused pharmacology with supportive cofacto...

More updates from Cannabis Bioscience International Holdings, Inc.